Formulary guidance and transparency from P&T to point of care

Market Access in Multiple Sclerosis

Posted by Jayne Hornung on Jun 1, 2015

Find me on:


An Increasing Prevalence?

Multiple sclerosis (MS) affects approximately 400,000 people in the US and 2.3 million worldwide. In the US, prevalence estimates are approximately 90 per 100,000 population. Signs of MS occur in most ethnic groups, but is more common in Caucasians of northern European ancestry. Multiple sclerosis symptoms can start anywhere between 10 and 80 years of age, but onset is usually between 20 and 40 years, with a mean of 32 years.1, 2

There is no definitive evidence that the incidence of MS is truly increasing, yet more people are being diagnosed with MS today than in the past. The reasons for this are not clear, though likely contributors include greater awareness of the disease, better access to medical care, and improved diagnostic capabilities.1

Multiple Sclerosis Treatments and Market Access

The current MS treatment landscape is crowded, with each drug having a different picture of market access. Most brands process almost exclusively through the pharmacy benefit, though as this current market access snapshot reveals, coverage is complex and all brands face restrictions on some plans, even when they may be preferred.MS_Market_Access

Source: MMIT data, current as of May 2015.

Staying Ahead of the Curve

While there are over a dozen brands on the market today for multiple sclerosis treatment, major clinical trials are currently testing novel approaches to treating all forms of MS, including progressive MS. Testing is underway to assess different approaches to protecting the nervous system from MS damage, including repurposing therapies already approved for other disorders. Furthermore, researchers are making headway to understand how the body’s gut microbiome may influence MS severity, which could lead to new approaches to halting MS progression. And there are a number of drugs in the near term pipeline for MS, including multiple companies pursuing a Copaxone biosimilar.

MMIT will equip your organization with class-specific data and analytics to provide a picture of the current market and to enable you to monitor changes as they occur. MMIT’s in-house team of pharmacists structure critical data about how multiple sclerosis therapies are managed and covered from complex, narrative policies on an ongoing basis.

We help companies understand their brand’s market access and competitive position in the MS treatment marketplace and can help put your organization ahead of the curve.

Want to learn more? Download our recent webinar.

Learn More




Topics: Specialty, Market Access